» Articles » PMID: 25497242

Comparison of Conventional and High-sensitivity Troponin in Patients with Chest Pain: a Collaborative Meta-analysis

Abstract

Background: Multiple studies have evaluated the diagnostic and prognostic performance of conventional troponin (cTn) and high-sensitivity troponin (hs-cTn). We performed a collaborative meta-analysis comparing cTn and hs-cTn for diagnosis of acute myocardial infarction (AMI) and assessment of prognosis in patients with chest pain.

Methods: MEDLINE/PubMed, Cochrane CENTRAL, and EMBASE were searched for studies assessing both cTn and hs-cTn in patients with chest pain. Study authors were contacted and many provided previously unpublished data.

Results: From 17 included studies, there were 8,644 patients. Compared with baseline cTn, baseline hs-cTn had significantly greater sensitivity (0.884 vs 0.749, P < .001) and negative predictive value (NPV; 0.964 vs 0.935, P < .001), whereas specificity (0.816 vs 0.938, P < .001) and positive predictive value (0.558 vs 0.759, P < .001) were significantly reduced. Based on summary receiver operating characteristic curves, test performance for the diagnosis of AMI was not significantly different between baseline cTn and hs-cTn (0.90 [95% CI 0.85-0.95] vs 0.92 [95% CI 0.90-0.94]). In a subanalysis of 6 studies that alternatively defined AMI based on hs-cTn, cTn had lower sensitivity (0.666, P < .001) and NPV (0.906, P < .001). Elevation of baseline hs-cTn, but negative baseline cTn, was associated with increased risk of death or nonfatal myocardial infarction during follow-up (P < .001) compared with both negative.

Conclusion: High-sensitivity troponin has significantly greater early sensitivity and NPV for the diagnosis of AMI at the cost of specificity and positive predictive value, which may enable early rule in/out of AMI in patients with chest pain. Baseline hs-cTn elevation in the setting of negative cTn is also associated with increased nonfatal myocardial infarction or death during follow-up.

Citing Articles

Contemporary Risk Stratification of Acute Coronary Syndrome.

Kaur G, Chand S, Rai D, Baibhav B, Blankstein R, Mukherjee D US Cardiol. 2024; 16:e23.

PMID: 39600828 PMC: 11588174. DOI: 10.15420/usc.2022.10.


Clinical Biochemistry of Serum Troponin.

Gokhan I, Dong W, Grubman D, Mezue K, Yang D, Wang Y Diagnostics (Basel). 2024; 14(4).

PMID: 38396417 PMC: 10887818. DOI: 10.3390/diagnostics14040378.


Chest Pain Risk Stratification in the Emergency Department: Current Perspectives.

Yukselen Z, Majmundar V, Dasari M, Arun Kumar P, Singh Y Open Access Emerg Med. 2024; 16:29-43.

PMID: 38343728 PMC: 10853047. DOI: 10.2147/OAEM.S419657.


Tunable Tamm plasmon cavity as a scalable biosensing platform for surface enhanced resonance Raman spectroscopy.

Sreekanth K, Perumal J, Dinish U, Prabhathan P, Liu Y, Singh R Nat Commun. 2023; 14(1):7085.

PMID: 37925522 PMC: 10625559. DOI: 10.1038/s41467-023-42854-7.


Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.

Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G Life (Basel). 2023; 13(10).

PMID: 37895374 PMC: 10608753. DOI: 10.3390/life13101992.